Last reviewed · How we verify
IPV at 14 and 22 weeks of age, RotaTeq
IPV at 14 and 22 weeks of age, RotaTeq is a Biologic drug developed by Centers for Disease Control and Prevention. It is currently FDA-approved.
At a glance
| Generic name | IPV at 14 and 22 weeks of age, RotaTeq |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPV at 14 and 22 weeks of age, RotaTeq CI brief — competitive landscape report
- IPV at 14 and 22 weeks of age, RotaTeq updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about IPV at 14 and 22 weeks of age, RotaTeq
What is IPV at 14 and 22 weeks of age, RotaTeq?
IPV at 14 and 22 weeks of age, RotaTeq is a Biologic drug developed by Centers for Disease Control and Prevention.
Who makes IPV at 14 and 22 weeks of age, RotaTeq?
IPV at 14 and 22 weeks of age, RotaTeq is developed and marketed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).
What development phase is IPV at 14 and 22 weeks of age, RotaTeq in?
IPV at 14 and 22 weeks of age, RotaTeq is FDA-approved (marketed).